Background Hepcidin is a key mediator of the anemia of chronic kidney disease (CKD). There is emerging evidence that 25-hydroxyvitamin D (25D) regulates hepcidin production. Methods A randomized controlled trial of daily vitamin D supplementation for 12 weeks was performed with the aim to test the effects of 4000 versus 400 IU of cholecalciferol on serum hepcidin levels in children with non-dialysis CKD recruited at a tertiary care children's hospital. Hepcidin was quantified using a validated competitive enzyme-linked immunosorbent assay. 25D levels were measured using the chemiluminescence Liaison 25(OH)D assay system. Covariables included hemoglobin, C-reactive protein, ferritin, and serum calcium and phosphorus for safety monitoring. Results A total of 34 subjects were randomized to either the intervention or control group, of whom 26.5% were female and 23.5% were African American. The mean age of the study cohort was 10.9 [standard deviation (SD) 5.8] years, the mean baseline glomerular filtration rate was 60 (SD 17.6) ml/min/ 1.73 m 2 , and mean baseline 25D level was 29.7 (SD 11.5) ng/ ml. At baseline, 50% of subjects were 25D deficient. There were no significant differences in baseline characteristics between the intervention and control groups. Treatment with 4000 IU cholecalciferol was not associated with significant change in hepcidin level at 4 or 12 weeks, and multivariable generalized estimating equation regression demonstrated no significant difference in change in hepcidin over the treatment period in either arm. The median C-reactive protein level decreased significantly at 12 weeks in the intervention group. Conclusions These results do not suggest that daily nutritional vitamin D supplementation modifies serum hepcidin levels in children with CKD. Further study will be required to determine whether supplementation may be effective in children with more advanced CKD or those on dialysis.
Introduction
The iron-regulatory protein hepcidin has emerged as a potentially modifiable mediator of the anemia of chronic kidney disease (CKD), including erythropoiesis stimulating agent (ESA)-resistant anemia. Although ESAs are effective for raising the hemoglobin level, clinical trials in adults have demonstrated that escalating ESA dose is associated with an increased risk for adverse cardiovascular events, stroke, and death [1, 2] . In addition, more than 20% of children with advanced CKD demonstrate hypo-responsiveness to ESA therapy [3] . There is therefore a need for alternative anemia therapies of decreased toxicity to adjunctively treat the anemia of CKD. Modification of hepcidin is an attractive potential target for this therapy.
Hepcidin, encoded by the HAMP gene, is synthesized as an 84-amino acid prepropeptide in the liver and then cleaved by the prohormone convertase furin to create the active 25-amino acid form [4] . Hepcidin production in humans is downregulated by hypoxia and anemia and upregulated by iron-loading and inflammation [5] [6] [7] . Hepcidin regulates intestinal iron absorption and body iron distribution through its posttranslational suppression of cell-membrane ferroportin expression [4] . When bound by hepcidin, ferroportin is internalized and degraded, leading to downregulation of dietary iron absorption by intestinal enterocytes and inhibition of the release of intracellular (in hepatocytes, monocytes) iron stored in ferritin for utilization in erythropoiesis [8] [9] [10] . The primary mechanism for clearance of circulating hepcidin is glomerular filtration and proteolysis in the proximal tubule, which is decreased in the setting of reduced glomerular filtration rate (GFR) [11] . Hepcidin levels are elevated in both adults and children with CKD and those on dialysis [10, 12, 13] . A recent analysis conducted within the framework of the Chronic Kidney Disease in Children (CKiD) longitudinal cohort study showed that in children with non-dialysis CKD, increased hepcidin levels are associated with decreasing hemoglobin levels and increased risk for incident anemia [14] .
Vitamin D has emerged as a potential novel regulator of hepcidin production, with localized 25-hydroxyvitamin D (25D) metabolism modulating cytokine production [15, 16] . Treatment of hepatocytes or monocytes with 25D has been shown to suppress HAMP expression in vitro, and high-dose vitamin D2/ergocalciferol supplementation has been shown to decrease circulating hepcidin levels in healthy subjects [17] . However, no study has tested the effect of daily nutritional vitamin D supplementation on hepcidin levels in children with CKD. We conducted a randomized, controlled trial to evaluate the efficacy of cholecalciferol supplementation to modify serum hepcidin levels in children with non-dialysis CKD.
Research design and methods

Study design and study population
This study was approved by the Johns Hopkins Institutional Review Boards. All participants aged 18 years and older provided written informed consent in adherence with the Declaration of Helsinki. For participants aged <18 years, written informed consent was provided by a parent/legal guardian. We performed a single-center, open-label, randomized, controlled trial of nutritional vitamin D3 supplementation as cholecalciferol at a dose of 4000 IU/day versus the estimated average requirement (EAR) of 400 IU/day [18] . The recruitment period was June 2012-December 2014 in the Johns Hopkins outpatient pediatric nephrology clinic via in-person approach of eligible subjects by a study coordinator during a routine clinic visit. The total treatment period was 12 weeks, with visits at baseline, 4, and 12 weeks. The clinicaltrials.gov registration number was NCT01532349.
Inclusion criteria were age of ≥ 1 and <21 years, and a clinical diagnosis of stage 2-5 non-dialysis CKD with estimated GFR (eGFR) of between 15 and 90 ml/min/1.73 m 2 using the bedside Schwartz equation [19] . Nutritional vitamin D supplements were discontinued at randomization to study arm when applicable and replaced with the study drug. Medication data, including the prescription of ESAs and iron supplements, were collected for all subjects, and doses remained stable throughout the study period. Exclusion criteria were history of hypercalcemia or nephrolithiasis; gastrointestinal tract discontinuity; current pregnancy or pregnancy within the last 12 months; kidney, liver, or heart transplant within the last 12 months; history of sickle cell anemia or thalassemia; or children with 25D levels of <5 ng/ml or >60 ng/ml at baseline.
Randomization and interventions
The intervention model was parallel assignment. Randomized assignments were generated using block stratification and a pseudorandom number generator. Intervention subjects were provided with a 4-week supply of 4000 IU/day cholecalciferol tablets at the baseline visit and an additional 8-week supply of tablets at the 4 week visit. Controls received 400 IU cholecalciferol tablets and received appropriate quantities at the 4 and 8 week visits. If unable to tolerate tablets, participants in both arms were supplied with Enfamil TM D-Vi-Sol TM 400 IU/ml liquid in the appropriate dose and volume. Randomization and drug dispensation were handled by the Pharmacy and Investigational Drug service at The Johns Hopkins Hospital. All participants, study staff, and analytic team members were masked to the randomization sequence.
Data collection and study outcomes
Participants provided blood samples at each visit and urine samples at the baseline and 4 week visits. Serum aliquots were stored at −80°C. Serum hepcidin was the primary outcome variable and was quantified at all visits. Previously frozen serum samples were batch shipped overnight to Intrinsic Lifesciences (La Jolla, California), and hepcidin-25 was quantified using a validated competitive enzyme-linked immunosorbent assay (ELISA) with sensitivity of 5 ng/ml and interassay variability of 12%, in a single laboratory [20] . Hemoglobin was a secondary outcome and was measured locally at Johns Hopkins. Serum vitamin D concentrations were measured in the Immunology Laboratory at the Johns Hopkins Hospital using the fully automated chemiluminescence immunoassay (DiaSorin, Stillwater, MN; www. diasorin.com), which measures both vitamin D2 and D3 and is reported as a total serum 25D concentration. The intra-assay coefficient of variation was <10% [21] . C-reactive protein (CRP), as a marker of inflammation (baseline, 4 and 12 weeks), and ferritin (baseline and 12 weeks), which has been shown to be correlated with hepcidin in previous studies, were measured locally in the Johns Hopkins Clinical Laboratory. In a sensitivity analysis, human interleukin 6 (IL-6) was measured in a subgroup of previously frozen serum samples using a commercially available ELISA kit (Quantikine® Human IL-6 Immunoassay; R&D Systems, Inc., Minneapolis, MN) with a minimum detectable dose of <0.07 pg/ml, an inter-assay coefficient of variation of 3.8-6.4% and an intra-assay coefficient of variation of 2-4.2% [22] . Serum samples were tested in duplicate according to the manufacturer's instructions, and the plates were read immediately after application of the stop solution. The optical density of each sample was determined using the VERSAmax tunable microplate reader (Molecular Devices, Sunnyvale, CA).
Safety monitoring
Serum calcium, phosphorus, and albumin (to calculate corrected total calcium level if the albumin level was <3.5 g/ dl) and urine calcium:creatinine ratios were measured at the baseline and 4 week visits to monitor for vitamin D toxicity. If subjects randomized to the intervention demonstrated hypercalcemia (serum total calcium of >10.8 mg/dl in those aged 1-5 years, >10.3 mg/dl in 6-12 year-olds, or >10.2 mg/dl in 13-20 year-olds), hyperphosphatemia (serum phosphorus of >6.5 mg/dl in those aged 1-5 years, >5.8 in 6-12 year-olds, or >4.5 in 13-20 year-olds), or hypercalciuria (urine calcium:creatinine ratio of >0.2) at the baseline visit, they were unenrolled from the study [22] . In addition, if intervent i o n s u b j e c t s d e m o n s t r a t e d h y p e r c a l c e m i a , hyperphosphatemia, or hypercalciuria at the 4 week visit, the study drug was discontinued; these subjects remained in the study and data at 12 weeks were collected. Subjects with 25D levels of <5 ng/ml at the baseline visit were unenrolled, as the clinically indicated vitamin D would be a higher dose than that available in the trial [23] . Finally, if 25D levels of ≥60 ng/ml were noted at the 4 week visit in intervention subjects, supplements were stopped due to increased risk for vitamin D toxicity, but 12 week data were still collected.
Statistical considerations
All analyses were based on intention-to-treat. Sample size for this study was based on estimates of the difference in change in serum hepcidin. We anticipated that a sample size of 34 participants would result in 90% power to detect a difference between the intervention and control groups in serum hepcidin of 50% at an α of 0.05, and would also provide 95% power to detect a 1 g/dl increase in hemoglobin with supplementation.
Statistical significance was set at p < 0.05. All analyses were performed using Stata version 14.0 (StataCorp LB, College Station, TX). Distributions of continuous variables were assessed for normality and were log transformed if indicated to assess correlations between variables. For normally distributed data, the mean ± standard deviation (SD) were reported, and changes between baseline and 4 and 12 week data were assessed using the paired t test. For skewed data, the median and interquartile range (IQR) were reported, and differences were assessed using the Wilcoxon signed-rank test. Multivariable generalized estimating equation (GEE) regression analysis was used to evaluate percentage change from baseline in hepcidin, 25D, hemoglobin, and CRP in control versus intervention groups. Variables which were not normally distributed were log-transformed for GEE analysis. GEE models utilized a Huber and White robust variance estimator [24] , which assumed an exchangeable working correlation matrix.
Results
Study participants
We screened 1472 potential participants during the recruitment period. Of 145 eligible subjects, 34 were randomized into the intervention or control arms (17 per arm). Figure 1 summarizes the flow of subjects. Baseline characteristics are presented in Table 2 . The mean baseline 25D level was 29.7 (SD 11.5), and 50% of subjects were noted to be vitamin D insufficient/deficient at baseline with a 25D level of <30 ng/ml. A small number of subjects, three in each arm, had baseline 25D levels of <20 mg/ml. There were no statistically significant baseline differences in demographic or clinical characteristics between the control and intervention groups, although the difference in proportion of subjects prescribed iron supplements at baseline by treatment arm approached significance (17.7% in the control arm vs. 41.2% in the intervention arm, p = 0.13) ( Table 1) .
Laboratory parameters
The 25D levels at baseline and 12 weeks by study arm are shown in Fig. 2 . At baseline the only significantly correlated variables were log hepcidin and log ferritin (r = 0.58, p < 0.001). Log hepcidin was also correlated with ferritin at the 12 week visit (r = 0.71, p < 0.001). Values at baseline and 4 and 12 weeks by study arm are presented in Table 2 . At 4 weeks, in the control arm, no significant differences were noted in any clinical parameters. In the intervention arm, the median 25D level increased from 32 [IQR 23, 30 ] to 38.5 [IQR 31, 50] ng/ml (p = 0.001), and there was a borderline-significant decrease in the prevalence of vitamin D insufficiency/deficiency from 47.1 to 14.3% (p = 0.05). At 12 weeks, no significant differences were noted in any clinical parameters of interest in the control arm. A significant increase in median 25D level was again seen in There were no significant differences in the observed changes in hepcidin, 25D, hemoglobin, or CRP noted between baseline and the follow-up visits at 4 and 12 week s in the control group (Table 3 ). In the intervention group, the 25D level increased significantly by 48.4 and 34.5% at both the 4 and 12 week visits compared to baseline, and the difference in the change in 25D levels was significantly different in the intervention versus control group (p = 0.003). Compared to the control group, the supplementation intervention significantly increased 25D levels [+41.8%; 95% confidence interval (CI) 12.9-78.2%]. A significant decrease (>60%) in CRP level between the baseline and 12 week visits was noted in the intervention group (−60.6%; 95% CI −83.5 to −6.4%); however, the difference in the change in CRP between the intervention and control groups did not reach statistical significance (−31.5%; 95% CI −76.3 to 97.5%).
Compliance and safety
The levels of 25D were significantly increased at 4 and 12 weeks in the intervention group and unchanged in the control group, suggesting compliance with the intervention. No subjects randomized to the control group demonstrated cholecalciferol-associated adverse events (AE) at the 4 week study visit. Three intervention subjects were unenrolled after the baseline visit due to safety parameters. Five subjects in the intervention arm had the study drug discontinued at the 4 week visit due to AE (Table 4) . No significant difference in baseline 25D levels in those with and without AE was noted, although the trend was for a higher level among those who sustained an AE.
Discussion
In this randomized, controlled trial, daily supplementation with 4000 IU cholecalciferol compared with the EAR of 400 IU/day, with a resulting significant increase in 25D levels in the intervention group, did not result in a significant change in serum hepcidin level after 4 or 12 weeks of treatment in children with non-dialysis CKD. The hemoglobin level did not change significantly in either arm. A significant decrease in CRP was noted between baseline and the 12 week visits in the intervention group, but the overall difference in change in CRP by study arm did not reach statistical significance.
Previous in vitro studies have demonstrated that treatment of cultured cells with 25D or 1,25-dihydroxyvitamin D results in decreased hepcidin mRNA expression via direct suppression of HAMP gene expression mediated by locally activated or administered 1,25-dihydroxyvitamin binding to the vitamin D receptor [17, 25] . In vivo, short-term suppression of hepcidin production by vitamin D has been previously reported by Bacchetta et al. who demonstrated that treatment of seven healthy adults with a single oral dose of 100,000 IU of vitamin D 2 /ergocalciferol resulted a 34% decrease in circulating hepcidin levels at 24 h and a 33% decrease at 72 h, notably without any significant change in circulating Bactivated1
,25-dihydroxyvitamin D levels [17] . Our study utilized cholecalciferol rather than ergocalciferol supplementation, but given that cholecalciferol's effectiveness in raising 25D levels is high, and in some studies has been demonstrated to be higher, compared to ergocalciferol (vitamin D2), the difference in formulation likely does not account for our observed lack of change in hepcidin concentration [26, 27] . However, the supplemental dose utilized by Bacchetta et al. far exceeds dietary reference values. Although vitamin D treatment is generally safe, it has been associated with increase urinary and serum calcium [28] , and in light of the results of our study in which five subjects treated with 4000 IU/day cholecalciferol demonstrated either hyperphosphatemia, hypervitaminosis D, or nephrolithiasis, it is not without risk. Notably, the magnitude of the change in circulating 25D levels observed by Bacchetta et al. (27 ± 2 to 43.5 ± 3 ng/ml) was similar to that seen with our intervention [17] . However, the more gradual increase in 25D observed in our trial was not associated with a decrease in hepcidin. Fibroblast growth factor 23 (FGF23) levels increased as well in Bacchetta et al.'s study, a potentially undesirable effect in patients with CKD [17] . Our findings did not demonstrate a significant decrease in circulating hepcidin level with supplementation using a dosing scheme that is commonly applied in clinical practice. With regard to our hypothesis that vitamin D3 supplementation could decrease hepcidin-mediated iron-restricted erythropoiesis, a trend for decreased median ferritin was noted between the baseline and 12 week visits in the intervention subjects which did not reach statistical significance (Table 2) ; this could reflect an increase in accessible, utilized iron in these subjects and is consistent with the direction of the non-significant trend for decreased hepcidin observed in this group. However, the limited sample size for this study may have limited the significance of these observations. Given the significant cost and potential adverse effects associated with escalating ESA therapy in CKD patients, vitamin D3 supplementation would be an attractive potential adjuvant therapy to modify hepcidin-mediated iron restriction. Vitamin D is now recognized for its multiple extra-skeletal effects, including innate immune system regulation. Local (non-renal) 25D hydroxylation is known to regulate innate immune function via local metabolism in immune cells [15, 16, 29] . It has been reported that locally activated 25D inhibits the production of inflammatory cytokines, including IL-6 and tumor necrosis factor alpha, and that inflammatory cytokines may serve to directly induce hepcidin production [12, 15, 16, 30, 31] . Alternatively, a recent study published by Smith et al. reported that high-dose vitamin D3 supplementation reduced plasma hepcidin concentrations in healthy adults without any change in plasma cytokine concentration, suggesting that vitamin D may play a role in the regulation of the hepcidin-iron axis independently of changes in proinflammatory cytokines [32] . There is accumulating evidence that nutritional 25D deficiency is a risk factor for anemia in both healthy people and in those with kidney disease and that hepcidin upregulation is likely a key mediator of anemia [33] [34] [35] . Vitamin D supplementation and correction of vitamin D deficiency have been associated with increased hemoglobin, decreased ESA dose requirement, and improvement in ESA-resistant anemia in dialysis patients [36] [37] [38] [39] , although a more recent study did not confirm these associations [40] .
We did observe a small but statistically significant decrease in CRP between baseline and 12 weeks in intervention subjects. However, as we did not measure inflammatory cytokine levels concurrently with hepcidin and 25D levels in the course of the study, we are unable to globally describe changes in markers of inflammation other than CRP in response to the intervention. Given the observed decrease in CRP level at 12 weeks in the intervention arm however, we did perform a post-hoc sensitivity analysis in a subgroup of intervention and control subjects, but found no significant change in serum IL-6 level from baseline to 12 weeks in either treatment arm; but given the very small sample size and the relatively low IL-6 levels observed, this result should not be taken to suggest that Reference values for serum hepcidin in children have been difficult to define, in part due to variation in available hepcidin assays (including ELISA and mass spectrometry), limiting comparisons across studies [41, 42] . A prior study using the same ELISA assay performed in the same laboratory as our study reported the median hepcidin level in healthy pediatric controls as 25.3 ng/ml, and in 48 children with stage 2-4 CKD as 127.3 ng/ml [12] . We previously described hepcidin levels in a cohort of 133 children with stage 2-4 CKD in the CKiD cohort study: the median baseline hepcidin level was higher in D-fense subjects than in the CKiD cohort ( [14] . However, despite a shift in the distribution of hepcidin levels to the left compared to the present study, increased risk for hemoglobin decline and incident anemia was noted in CKiD subjects with higher baseline hepcidin levels [14] .
At baseline 50% of subjects in this study were vitamin D insufficient or deficient. The recognition of vitamin D deficiency and its associated risks (including extra-skeletal risks) by nephrology providers has increased substantially over the last 10 years, with clinical practice guidelines for the diagnosis and management published by the National Kidney Foundation Kidney Disease Outcomes and Quality Initiative in 2008 [23] . Using the currently established threshold for vitamin D insufficiency and deficiency, our data suggest this is an ongoing problem requiring vigilant monitoring and treatment. The separate and important question of whether current vitamin D thresholds are associated with patient outcomes is beyond the scope of this analysis.
The strengths of this pilot study include its prospective, randomized, controlled design. The relatively short intervention period allowed for assessment of the acute effects on serum hepcidin without significant changes in GFR or therapeutic regimen in children with stable non-dialysis CKD. The major limitations are a small sample size, which was determined in part with an estimated 50% change in hepcidin in the intervention group; although serum hepcidin levels have been shown to decrease promptly and significantly in patients undergoing hemodialysis [13] , the potential reduction may be significantly smaller in response to vitamin D supplementation. The analysis was also limited by increased rates of postrandomization ineligibility and AE in the intervention group leading to discontinuation of the intervention after 4 weeks of treatment in five subjects. Additionally, intra-individual and diurnal variability in hepcidin levels has been reported [43] . Healthy subjects demonstrate iron-independent diurnal variation in hepcidin, with levels being lowest in the morning and increasing steadily throughout the day [44, 45] . Given the challenges of scheduling patients for study visits in the context of school and parents' work schedules, we were unable to collect blood samples for hepcidin at standardized times across the study; this may have increased the variability of the measurements, resulting in underestimation of the effect size of any change in hepcidin observed in the intervention group. In addition, we observed a non-significant trend for more intervention patients to be prescribed iron supplements compared to controls; since iron treatment can increase hepcidin levels [42] , this could have contributed to underestimation of change in hepcidin in the intervention group.
In conclusion, in this randomized controlled clinical trial, the first such trial conducted in children with CKD, effective vitamin D 3 supplementation failed to modify the primary outcome of hepcidin level; these results do not support a shortterm benefit of supplementation as an adjunctive treatment for anemia. Nevertheless, the measurement of hepcidin in patients with CKD and the investigation of interventions that could serve to modify its production remain an attractive strategy in the development of novel targets for anemia therapy. Further study will be required to determine whether this intervention may be more effective in children with advanced CKD or on dialysis, or in patients supplemented for longer periods of time. Going forward, multicenter trials will be critical to amass sample sizes required to detect even small differences in hepcidin concentration.
